CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The MicroCaT project seeks to validate IndiTreat, a personalized cancer treatment test that uses 3D cell cultures from patients' tumors. This approach aims to identify the most effective and least toxic drug regimens for colorectal cancer, improving patient outcomes and reducing healthcare costs.
Every year around 350.000 patients in the EU are newly diagnosed with colorectal cancer (CRC).
Although € 1.4 Billion are spent on CRC drugs, the majority of patients fail to respond to therapy because their individual tumor is resistant to the chosen treatment.
These patients suffer from unwanted side effects and after two month are switched to another drug regime – giving rise to additional drug and hospital costs. 2cureX ApS, a Danish SME, has developed IndiTreat, an ex-vivo chemosensitivity…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, HAMBURG
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
